Nobelpharma Co., Ltd.
February 23, 2015

Launch of “Zanosar IV Infusion 1 g” for Teatment of Cancer (Gastroenteropancreatic
Neuroendocrine Tumors)
Nobelpharma Co., Ltd. (Headquarters: Tokyo, President: Jin Shiomura) today announces the launch of"Zanosar IV Infusion 1g" (generic name: streptozocin or STZ), a drug for the treatment ofgastroenteropancreatic neuroendocrine tumor as of February 23.
Since the approval in the U.S. obtained by an American company, Upjohn (currently Pfizer), in 1982 for theindication of symptomatic or progressive metastatic pancreatic islet cell cancer, STZ has been used for a longtime for the treatment of gastroenteropancreatic neuroendocrine tumor ("GEP NET") as a monotherapy or incombination with doxorubicin (DOX) or fluorouracil (5-FU).
In Japan, upon the request from the Ministry of Health, Labour and Welfare as a result of "Evaluation
Committee on Unapproved or Off-label Drugs with High Medical Needs," Nobelpharma started thedevelopment and conducted Phase I/II study of Zanosar in patients with unresectable or metastatic GEP NET.
Zanosar was designated as an orphan drug for the indication of GEP NET on November 16, 2011 and wasapproved for marketing under the brand name of "Zanosar IV Infusion 1g" on September 26, 2014. Zanosar ismanufactured, distributed and marketed nationwide by Nobelpharma Co., Ltd.
Zanosar is the first cytotoxic anti-cancer drug for treatment of GEP NET in Japan, leading to an expansionof the treatment options for patients with unresectable or metastatic GEP NET. Nobelpharma is commited toaddress the issues of rare disease treatments through Zanosar continuing to contribute to society by providing
drugs for unmet medical needs.
Nobelpharma will conduct postmarketing surveillance on all patients receiving Zanosar to collect safety
and efficacy data for certain period of time from its launch.
END[Contacts]
Nobelpharma Co., Ltd.
Tsutomu Sugaya, Senior Executive Officer, Head of Corporate Planning and Administration
12-10, Nihonbashi-kobunacho, Chuo-ku, Tokyo 103-0024
Tel: 03-5651-1160

[Product Profile]
Brand Name: Zanosar IV Infusion 1g
Generic Name: streptozocin
Indication: gastroenteropancreatic neuroendocrine tumor
Package: 1 vial
Dosage and Administration: Either as a weekly treatment (once a week) or as a daily treatment for 5
consecutive days every 6 weeks
NHI Drug Price: 42,531 yen
Manufacturer: Nobelpharma Co., Ltd.
Product Website: http://nobelpark.jp/* GEP NET is a relatively rare tumor with the annual incidence of 3 to 5 per 100,000 people, and 2015
estimation of the number of candidates for drug therapy is about 3,600.

About Nobelpharma
Nobelpharma has been contributing to medical care through R&D of necessary but neglected pharmaceuticals
since 2003. Nobelpharma gives priority in developing pharmaceuticals desired strongly by patient groups, theJapan Medical Association, and other organizations with the intent to fill the unmet medical needs. Focusing
mainly on orphan drugs, additional indications for drugs used off-label, and pediatric medicines, Nobelpharma
has obtained marketing approvals for 14 products primarily for unmet medical needs, of which 9 aredesignated as orphan drugs.
END